Alnylam is the biotech industry pioneer leading the translation of RNA interference (RNAi) into an innovative approach to medicine. The US-based company established its European headquarters in Zug in the Greater Zurich Area in 2016.
RNAi has the potential to transform the treatment of patients with life-threatening diseases for whom few or no alternative therapies exist. For the past 15 years, Alnylam has built upon this bold vision and now has three late-stage treatments in clinical development for the treatment of hereditary ATTR amyloidosis, hemophilia and other rare bleeding disorders, and acute hepatic porphyrias.
Based in Cambridge, Massachusetts (USA), Alnylam established its European headquarters in the life sciences hub of Zug in the Greater Zurich Area in 2016. "Providing access to top talent, Zug in the Greater Zurich Area offers the ideal location for Alnylam to begin this expansion," Emmanuel Dulac, Chief Commercial Officer of Alnylam Pharmaceuticals, explains. Alnylam's Zug office houses critical roles on the Commercial Leadership Team – responsible for the delivery of its future medicines to patients across Europe – as well as key corporate functions including Business Development, Human Resources, Legal and Information Technology.
Related Success Stories
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line.